文献速递前列腺癌

晚期前列腺癌患者快速基因检测模型的临床影响

Clinical Impact of a Rapid Genetic Testing Model for Advanced Prostate Cancer Patients.
PubMed 文献 · J Urol · 2023-03-28

这项多中心单臂前瞻性试验评估了由肿瘤科医生发起、遗传咨询师协作的胚系基因检测模型在晚期前列腺癌患者中的可行性与临床影响。501例受试者中51例(10.2%)检出至少1个致病/可能致病变异,48例可评估阳性者中22例(45.8%)讨论了治疗改变。受试者对检测前教育和检测决策的满意度均较高,结果回报中位时间为采样后20天。

要点

  • 501例晚期前列腺癌患者中51例(10.2%)检出至少1个致病/可能致病变异。
  • 48例可评估阳性患者中22例(45.8%)讨论了治疗改变。
  • 检测前教育满意度15.5±2.2、检测决策满意度17.1±2.9(均为4-20分制),结果回报中位时间20天。

核心结论

  • 由肿瘤科医生发起、遗传咨询师协作的胚系基因检测是检测晚期前列腺癌患者且具有实际临床可操作性的可行方法。
  • 该检测模型和教育材料可作为治疗前列腺癌患者的临床医生的资源。

研究设计与样本

  • 多中心、单臂前瞻性试验。
  • 晚期前列腺癌患者由其肿瘤科医生转诊,检测14个与遗传性前列腺癌相关的基因。
  • 在肿瘤科门诊提供检测前教育(宣传册和视频),遗传咨询师通过电话联系受试者获取家族史并讨论结果。
  • 共501例受试者同意进行胚系分析。

主要发现

  • 501例受试者中51例(10.2%)检出至少1个致病/可能致病变异。
  • 48例可评估的阳性受试者中22例(45.8%)讨论了治疗改变。
  • 检测前教育满意度平均±SD为15.5±2.2(4-20分制),检测决策满意度为17.1±2.9(4-20分制),均较高。
  • 结果在采样后中位20天回报。

临床怎么用

  • 原文结论认为该检测模型和教育材料可作为治疗前列腺癌患者的临床医生的资源。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Genetic testing may alter clinical management for individuals with metastatic prostate cancer by identifying additional therapies. Traditional counseling models are unlikely to enable time-sensitive therapeutic decision-making. This study aimed to determine the feasibility and clinical impact of an alternative hereditary genetic testing model. MATERIALS AND METHODS: As part of a multicenter, single-arm prospective trial, individuals with advanced prostate cancer were referred by their oncologist for testing of 14 genes associated with hereditary prostate cancer. Pretest education (brochure and video) was provided in the oncology clinic. Questionnaires assessing participant satisfaction with both pretest education and decision to undergo genetic testing were collected. A genetic counselor contacted participants by phone to obtain family history and discuss results. Medical records were queried to determine whether a change in clinical management was discussed. RESULTS: Of 501 participants consented to germline analysis, 51 (10.2%) had at least 1 pathogenic/likely pathogenic variant. Change in treatment was discussed with 22/48 (45.8%) of eligible participants who tested positive. Feasibility of this model was assessed by participant satisfaction and turnaround time. Average±SD satisfaction with the pretest education (15.5±2.2, 4-20 scale) and with the decision to undergo genetic testing (17.1±2.9, 4-20 scale) were both high. Results were returned 20 days (median) after sample collection. CONCLUSIONS: Oncologist-initiated germline genetic testing in collaboration with a genetic counselor is a feasible approach to testing advanced prostate cancer patients with impactful clinical actionability. The testing model and educational material serve as resources to clinicians treating prostate cancer patients.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Breen KE, Symecko H, Spielman K, et al. Clinical Impact of a Rapid Genetic Testing Model for Advanced Prostate Cancer Patients. J Urol. 2023. PMID: 36974724. doi:10.1097/JU.0000000000003186

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。